PNEUMOVAX 23 Rx
Generic Name and Formulations:
Pneumococcal vaccine 25mcg; each of 23 polysaccharide isolates; inj; contains phenol.
Merck & Co., Inc.
Indications for PNEUMOVAX 23:
Immunization against pneumococcal disease caused by approximately 85–90% of common U.S. isolates.
Adults and Children:
<2yrs: not recommended. ≥2yrs: 0.5mL IM or SC once in deltoid muscle or lateral mid-thigh.
Not for routine revaccination after previous pneumococcal vaccination in immunocompetent patients. Within 14 days of immunosuppressive therapy.
Severe cardiac or pulmonary disease where a systemic reaction would pose a significant risk. May defer in acute febrile respiratory illness or other active infection. Do not discontinue antipneumococcal prophylactic antibiotic therapy. Have epinephrine inj (1:1000) available. Pregnancy (Cat.C). Nursing mothers.
Inj site reactions, low grade fever.
Multidose vials—1,10; Single-dose vials—10
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies